Inhibition of neutrophil respiratory burst and degranulation responses by CVT-E002, the main active ingredient in COLD-FX by Renjith Pillai & Paige Lacy
MEETING ABSTRACT Open Access
Inhibition of neutrophil respiratory burst and
degranulation responses by CVT-E002, the main
active ingredient in COLD-FX
Renjith Pillai, Paige Lacy*
From Canadian Society of Allergy and Clinical Immunology Annual Scientific Meeting 2011
Quebec, Canada. 20-23 October 2011
Background
Human peripheral blood neutrophils contribute to the first
line of defence in the immune system and are critical for
maintaining health and immunity against opportunistic
infections. Neutrophils and their granule-derived media-
tors are frequently found elevated in patient samples in
viral infections, asthma exacerbations, and other respira-
tory ailments. COLD-FX has been shown to reduce the
symptoms and severity of respiratory tract viral infections.
Our hypothesis is that COLD-FX modulates neutrophil
activity. To determine the effects of COLD-FX on neutro-
phils, peripheral blood neutrophils (>97% purity) were iso-
lated from healthy human volunteers.
Methods
Neutrophils were preincubated with varying doses of
CVT-E002 (0.01-1 mg/ml), the active ingredient of
COLD-FX, for 30, 60, and 120 min. Extracellular ROS
production was measured by cytochrome c reduction
from neutrophils stimulated with 50 ng/ml phorbol myris-
tate acetate for up to 60 min. Degranulation was measured
by the presence of extracellular myeloperoxidase, a marker
of the azurophilic granules, in neutrophils stimulated with
cytochalasin B and f-Met-Leu-Phe for 15 min.
Results
CVT-E002 (1 mg/ml) had no significant effect on viability
at up to 120 min of incubation. At 60 min of incubation
with CVT-E002, neutrophils showed a 30% reduction in
ROS generation (p < 0.001) which was maintained for up
to 120 min. Preliminary experiments also showed that
incubation of neutrophils with CVT-E002 for 30 min
inhibited myeloperoxidase release.
Conclusions
These novel findings demonstrate that COLD-FX signifi-
cantly reduces activation of neutrophils. The implications
of this study are that COLD-FX may reduce oxidative
stress and tissue-damage triggered by neutrophilic
inflammation and activation.
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